Form 4: PROVECTUS BIOPHARMACEUTICALS CEO Converts Promissory Note to Preferred Stock

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., has converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, as disclosed in a recent SEC Form 4 filing.

Summary

• Edward Pershing, the CEO and Director of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), filed a Form 4 disclosing a change in beneficial ownership.
• On June 20, 2025, an 8% Unsecured Convertible Promissory Note (the "2022 Note") with a principal amount of $50,000 was converted into 18,880 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share of Series D-1 Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share.
• The 18,880 shares of Series D-1 Preferred Stock are convertible into 188,800 shares of Common Stock.
• Following this transaction, Mr. Pershing beneficially owns 2,110,732 shares of Common Stock directly.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted voluntarily.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The conversion of a note into equity by the CEO can be seen as a positive sign of commitment, though it also introduces potential future dilution. It's a pre-planned event, not a new investment or divestment.

Positives

• The conversion of the 8% Unsecured Convertible Promissory Note into equity (preferred stock) by the CEO can be viewed as a sign of continued commitment to the company.
• It reduces the company's outstanding debt, albeit by converting it into a different form of equity.

Negatives

• The conversion of preferred stock into common stock represents potential future dilution for existing common shareholders, as each preferred share converts into 10 common shares.

Risks

• Potential future dilution of common stock due to the conversion of Series D-1 Convertible Preferred Stock into common shares.
• The terms of the original 2022 Financing, under which the 2022 Note was issued, could carry other risks not detailed in this specific Form 4.

Future Outlook

The Series D-1 Convertible Preferred Stock acquired will automatically convert into Common Stock on June 20, 2026, unless voluntarily converted earlier in accordance with its terms.

Management Comments

• The filing itself is a required disclosure by Edward Pershing, CEO and Director, detailing a change in his beneficial ownership of company securities.

Industry Context

This Form 4 filing is a routine insider transaction disclosure common across all industries, indicating a change in a key executive's holdings. It does not provide specific insights into broader industry trends beyond the company's capital structure decisions.

Related Party Transactions

• The transaction involves Edward Pershing, the CEO and Director of the company, converting a promissory note into preferred stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock upon conversion of the Series D-1 Preferred Stock, but also a signal of insider commitment.
• Creditors: The conversion of the promissory note reduces the company's outstanding debt obligations.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026, unless earlier converted voluntarily.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Convertible Promissory Note, Preferred Stock, Common Stock, Equity Conversion, PROVECTUS BIOPHARMACEUTICALS, PVCT, Edward Pershing, Beneficial Ownership